JAMESTOWN
20.12.2019 12:32:04 CET | Business Wire | Press release
U.S. real estate investment and management company Jamestown , most notably known for projects like Chelsea Market in New York, today announced it has acquired Rotterdam’s historic Groot Handelsgebouw, its first large format acquisition in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005035/en/
The 122,000-square meter (approximately 1.3 million square foot) historic structure, located in the heart of Rotterdam next to the Central Station and 20 minutes from Schiphol airport, is emblematic of the city’s redevelopment after World War II. The building will now become a symbol of the innovation economy. Built in 1953 to help fulfil an acute need for office space Groot Handelsgebouw has become one of the largest mixed-use buildings in the Netherlands housing more than 450 businesses. Jamestown acquired the building from an investment vehicle managed by real estate private equity firm HighBrook Investors for a purchase price of €289 million. HighBrook had previously acquired the asset in July 2018 for approximately €169 million through an off-market public-to-private transaction involving the legacy Dutch listed company (EuroNext: GROHA).
“Groot Handelsgebouw is at the heart of Rotterdam’s history of growth and regeneration; we hope to continue that legacy with a new chapter through creating a hub for the new innovation economy,” said Michael Phillips, President of Jamestown.
Jamestown is a design-focused real estate company whose mission is to transform iconic spaces into innovation hubs and community centers. Its retail, local community, and mixed-use projects include Chelsea Market and Industry City in New York, Ghirardelli Square in San Francisco, Ponce City Market in Atlanta, and The Innovation and Design Building in Boston. Groot Handelsgebouw fits this diverse portfolio of adaptive reuse projects and is the first transaction led by the company’s new European team. Their Netherland’s asset management group is based in Amsterdam out of the historic bicycle factory A Factorij, which Jamestown entered into a partnership on in 2018.
HighBrook was advised on the transaction by Jones Day and Loyens & Loeff as well as its Asset Manager, Equity Estate. Jamestown was advised by Greenberg Traurig.
About Jamestown
Jamestown, LP was established in 1983 as an investment and management company focused on income-producing real estate in the United States. Jamestown companies employ approximately 450 people worldwide with headquarters in Atlanta, Georgia, and Cologne, Germany. The company has offices in Amsterdam, Bogotá, Boston, Los Angeles, New York, and San Francisco.
Since its founding, Jamestown has executed transactions in excess of $35 billion. As of 30 September 2019, the company has assets under management of $11.5 billion. Capital sources with a long term investment horizon are institutional investors, retail investors, and separate accounts.
As well as the traditional functions of a real estate management company, Jamestown possesses internal expertise that adds value to all aspects of the real estate business. Its in-house capabilities in Development & Construction, Architecture & Design, Sustainability, Retail Leasing, Creative & Marketing, and Food & Beverage curation, Jamestown maximizes value throughout an asset’s ownership period. See also www.jamestownlp.com .
About HighBrook Investors
HighBrook Investors is a private equity real estate manager that specializes in sourcing and identifying unique opportunities for value investing across market cycles. We utilize our collective experience investing in private, public, domestic, and developed international markets to identify situational opportunities across property types at optimal stages of the investment cycle. The firm was founded in 2010 and operates through its main offices in New York and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom